Clinical Trials Logo

Extramedullary Plasmacytoma clinical trials

View clinical trials related to Extramedullary Plasmacytoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04166565 Active, not recruiting - Multiple Myeloma Clinical Trials

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

EMN19
Start date: October 31, 2019
Phase: Phase 2
Study type: Interventional

This trial will try to establish the feasibility and efficacy of the combination of DaraVCD in Multiple Myeloma (MM) patients presenting with extramedullary disease (EMD). The study will be conducted as a Phase II trial. Forty patients will be included in the study cohort. All patients will be followed closely for toxicities and response assessment. After completion of treatment, patients will be followed every 6 months for survival until 5 years after enrolment